Form 4: Century Therapeutics' Chief Operations Officer Reports Stock Transactions

Adrienne Farid, Chief Operations Officer of Century Therapeutics, reports the sale of shares to cover tax obligations and the grant of restricted stock units and stock options.

Summary

• On March 10, 2025, Adrienne Farid, the Chief Operations Officer of Century Therapeutics, sold 2,359 shares of common stock at a price of $0.615 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• On March 11, 2025, Ms. Farid was granted 120,000 restricted stock units (RSUs) and a stock option to purchase 120,000 shares of common stock at an exercise price of $0.601.
• The RSUs vest 25% on March 11, 2026, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• The stock option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• Following these transactions, Ms. Farid beneficially owns 251,717 shares of Century Therapeutics common stock and holds options for 120,000 shares.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports stock transactions by a company executive, which is a routine occurrence. The grants of RSUs and stock options are generally viewed positively as they align management's interests with shareholders.

Positives

• The grant of RSUs and stock options to the COO aligns her interests with the long-term success of the company.
• The vesting schedules of the RSUs and stock options incentivize continued service and commitment from the COO.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest an expectation of continued service from the COO.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in the biotechnology industry, aligning their interests with shareholders.
• Vesting schedules are also typical, encouraging long-term commitment and performance.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a key executive.
• Employees may be interested in the compensation structure for executives.

Key Dates